Cellectis soars as Pfizer fronts $80m for immuno-oncology
This article was originally published in Scrip
Pfizer is paying $80m up front to French company Cellectis for access to its CAR-T platform, an allogeneic cell therapy approach to treating cancer with the aim of developing 'off-the-shelf' immunotherapies. Cellectis's Chimeric Antigen Receptor T-cell (CAR-T) technology uses engineered T-cells from a single donor for use in multiple patients, compared with autologous approaches which require engineering of a patient's own T-cells to target tumor cells.
You may also be interested in...
Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.
Excitement around cell therapy has been building in recent years, but companies expect interest to accelerate after Gilead agreed to buy Kite for $11.9bn and Novartis won the first ever CAR-T approval.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.